LAVA 1433
Alternative Names: LAVA-1433Latest Information Update: 08 Mar 2024
At a glance
- Originator Lava Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Intraepithelial lymphocyte agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours